prikaz prve stranice dokumenta Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
  Download
PDF 289.29 KB
Scientific paper - Original scientific paper
Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
Multiple Sclerosis and Related Disorders, 17 (2017); 151-153. https://doi.org/10.1016/j.msard.2017.07.019
Šega-Jazbec, Saša; Barun, Barbara; Horvat Ledinek, Alenka; Fabekovac, Višnja; Krbot Skorić, Magdalena; Habek, Mario

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šega Jazbec, S., Barun, B., Horvat Ledinek, A., Fabekovac, V., Krbot Skorić, M. & Habek, M. (2017). Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 17., 151-153. doi: 10.1016/j.msard.2017.07.019

Šega Jazbec, Saša, et al. "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis." Multiple Sclerosis and Related Disorders, vol. 17, 2017, pp. 151-153. https://doi.org/10.1016/j.msard.2017.07.019

Šega Jazbec, Saša, Barbara Barun, Alenka Horvat Ledinek, Višnja Fabekovac, Magdalena Krbot Skorić and Mario Habek. "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis." Multiple Sclerosis and Related Disorders 17 (2017): 151-153. https://doi.org/10.1016/j.msard.2017.07.019

Šega Jazbec, S., et al. (2017) 'Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis', Multiple Sclerosis and Related Disorders, 17, pp. 151-153. doi: 10.1016/j.msard.2017.07.019

Šega Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek M. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders [Internet]. 2017 October [cited 2024 April 29];17:151-153. doi: 10.1016/j.msard.2017.07.019

S. Šega Jazbec, B. Barun, A. Horvat Ledinek, V. Fabekovac, M. Krbot Skorić and M. Habek, "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis", Multiple Sclerosis and Related Disorders, vol. 17, pp. 151-153, October 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:902880. [Accessed: 29 April 2024]

Metadata
Title (english)Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
AuthorSaša Šega-Jazbec
AuthorBarbara Barun
AuthorAlenka Horvat Ledinek
AuthorVišnja Fabekovac
AuthorMagdalena Krbot Skorić
AuthorMario Habek
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVE: Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols. ----- METHODS: This was retrospective chart review of 38 consecutive MS patients who were treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, University Hospital Center Zagreb, Croatia and Department of Neurology, University Medical Center Ljubljana, Slovenia. ----- RESULTS: Seventeen patients (44.7%) did not experience IARs. Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions and they were most frequent on Day 5 and Day 1, respectively. We have observed significant differences in the occurrence of fever (p = 0.005) depending on the site of alemtuzumab administration which could be explained by different antipyretics used; fever was absent in the Slovenian cohort because high dose intravenous metamizole was administered. Two out of 9 treatment naïve, and 19 out of 29 patients who previously received immunomodulatory treatment had IARs (χ2 = 5.208, p = 0.022). ----- CONCLUSION: Modified premedication scheme consisting of 1g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleMultiple Sclerosis and Related Disorders
Numberingvol. 17, pp. 151-153
p-ISSN2211-0348
DOIhttps://doi.org/10.1016/j.msard.2017.07.019
URN:NBNurn:nbn:hr:105:902880
Publication2017-10
Document URLhttps://doi.org/10.1016/j.msard.2017.07.019
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:17:28